US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...
The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...
RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...
The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
The pharmaceutical industry has reminded the Spanish government of the commitments that it has made to the country during a meeting with Prime Minister Pedro Sánchez.
The FDA approved brentuximab vedotin (Adcetris) in combination with lenalidomide (Revlimid) and rituximab for relapsed or ...
The US Food and Drug Administration (FDA) approved expanding the prescribing information for Japanese drugmaker Astellas ...
James reiterated its Strong Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS), with a price target of $78.00. The stock, ...
Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...
IZERVAY dosing approved beyond 12 monthsTOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Ok ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback